<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529813</url>
  </required_header>
  <id_info>
    <org_study_id>2013-1018</org_study_id>
    <secondary_id>NCI-2015-01492</secondary_id>
    <secondary_id>20152145</secondary_id>
    <secondary_id>1159157</secondary_id>
    <secondary_id>2013-1018</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02529813</nct_id>
  </id_info>
  <brief_title>CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies</brief_title>
  <official_title>CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziopharm Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells
      in treating patients with lymphoid malignancies that have spread to other places in the body
      and usually cannot be cured or controlled with treatment. Sometimes researchers change the
      deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells
      that support the immune system) using a process called &quot;gene transfer.&quot; Gene transfer
      involves drawing blood from the patient, and then separating out the T-cells using a machine.
      Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the
      changed T-cells into the body of the patient. Injecting modified T-cells made from the
      patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and maximum tolerated dose of genetically modified, CD19-specific
      T cells administered into patients with CD19+ advanced lymphoid malignancies.

      SECONDARY OBJECTIVES:

      I. To screen for the development of host immune responses against the CD19-specific chimeric
      antigen receptor (CAR).

      II. To describe the homing ability of the infused T cells. III. To assess disease response.
      IV. To determine persistence of CAR+ T cells.

      OUTLINE: This is a dose escalation study of CD19 positive chimeric antigen receptor T-cells.

      LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of
      fludarabine phosphate intravenously (IV) over 1 hour and cyclophosphamide IV over 3 hours on
      days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the
      treating physician.

      Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric
      antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0
      and 1.

      After completion of study treatment, patients are followed up for at least 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of genetically modified, CD19-specified T cells</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be defined as the highest dose for which the posterior probability of toxicity is closest to 25%. Demographic and clinical characteristics will be summarized using descriptive statistics by dose level. The number of patients with dose limiting toxicities will be reported at each dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients for which a T cell product could not be prepared</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Computed with a corresponding 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing response (complete response and partial response)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Estimated with a corresponding 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Blasts 5 Percent or More of Bone Marrow Nucleated Cells</condition>
  <condition>CD19 Positive</condition>
  <condition>Minimal Residual Disease</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I (CD19 positive chimeric antigen receptor T-cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of fludarabine phosphate IV over 1 hour and cyclophosphamide IV over 3 hours on days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the treating physician.
Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0 and 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (CD19 positive chimeric antigen receptor T-cells)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (CD19 positive chimeric antigen receptor T-cells)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (CD19 positive chimeric antigen receptor T-cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tisagenlecleucel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (CD19 positive chimeric antigen receptor T-cells)</arm_group_label>
    <other_name>CART-19</other_name>
    <other_name>CART19</other_name>
    <other_name>CTL019</other_name>
    <other_name>CTL019 T-cells</other_name>
    <other_name>Kymriah</other_name>
    <other_name>Tisagenlecleucel-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a history of CD19+ lymphoid malignancy defined as acute lymphoblastic
             leukemia, acute biphenotypic leukemia, non-Hodgkin's lymphoma, small lymphocytic
             lymphoma, or chronic lymphocytic leukemia with active disease defined by presence of &gt;
             5% malignant blasts in bone marrow and/or peripheral blood, and/or minimal residual
             disease by flow cytometry or molecular analysis for fusion proteins, and/or positive
             imaging for extramedullary disease; patients must have measurable disease at time of
             study treatment

          -  Confirmed history of CD19 positivity by flow cytometry for malignant cells

          -  Lansky/Karnofsky performance scale &gt; 60%

          -  Patient able to provide written informed consent; parent or guardian of minor patient
             able to provide written informed consent

          -  Patient able to provide written informed consent for the long-term follow-up gene
             therapy study: 2006-0676; parent or guardian of minor patient able to provide written
             informed consent for the long-term follow-up gene therapy study: 2006-0676

        Exclusion Criteria:

          -  Positive beta human chorionic gonadotropin (HCG) in female of child-bearing potential
             defined as not post-menopausal for 12 months or no previous surgical sterilization or
             lactating females

          -  Patients with known allergy to bovine or murine products

          -  Positive serology for human immunodeficiency virus (HIV)

          -  Active hepatitis B or active hepatitis C

          -  Has received donor lymphocyte infusion (DLI) product within 6 weeks of CAR T cell
             infusion

          -  Has received allogeneic hematopoietic stem cell transplant within 3 months of CAR T
             cell infusion; hematopoietic stem cell transplant (HSCT) &gt; 3 months from CAR T cell
             infusion eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

